Vancouver-based Algernon Health (CSE:AGN, OTCQB:AGNPF) is charting a new course in healthcare, setting its sights on one of the fastest-growing frontiers: neuroimaging for Alzheimer's disease. Once a drug-repurposing company known as Algernon Pharmaceuticals, the firm has pivoted into medtech, unveiling a brain-focused PET scanner and laying the groundwork for a network of dedicated imaging centers across North America.
Algernon Health (CSE:AGN, OTCQB:AGNPF) said on Monday it has signed a strategic business and investment agreement with US-based American Molecular Imaging (AMI) to provide exclusive radiology reading services for its planned network of brain-focused PET neuroimaging clinics in the US. Algernon said the facilities, slated to begin opening in early 2026, will be the first dedicated brain-optimized PET neuroimaging clinics in the country, aimed at early detection of Alzheimer's disease as well as other dementias, epilepsy, neuro-oncology and movement disorders.
Wag! Group Co. (NASDAQ:PET ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Greg Robles - IR Garrett Smallwood - CEO and Chairman Adam Storm - President and Chief Product Officer Alec Davidian - CFO Operator Good morning. Welcome to the Wag!
| Software Industry | Information Technology Sector | Garrett Smallwood CEO | CXA Exchange | US93042P1093 ISIN |
| US Country | 64 Employees | - Last Dividend | - Last Split | 9 Aug 2022 IPO Date |
Wag! Group Co. is an innovative technology company that revolutionized how pet parents connect with independent pet caregivers. Founded in 2014 and based in San Francisco, California, Wag! has developed a comprehensive marketplace technology platform accessible through both a website and a mobile app. This platform serves as a bridge between pet parents seeking various pet care services and qualified independent pet caregivers. The core vision of Wag! focuses on making pet care easier, more convenient, and reliable for pet parents everywhere.